GSK Prunes Ties with US Biotech Vir

GSK is pruning its cooperation with Vir Biotechnology, turning away from Covid-19 antibody and vaccine research projects while continuing to collaborate with the company on two pandemic assets and programs to treat other respiratory diseases.

In April 2020, the British pharma invested an initial $250 million in the US infectious disease-oriented biotech as part of a four-year project to advance two Covid antibodies. In 2021 it put down $225 million upfront, while investing $120 million to expand the collaboration to cover influenza and other respiratory diseases.

In the current realignment, the partners are eliminating the Covid vaccine program from the antibody part of their 2020 agreement, with the exception of sotrovimab and VIR-7832.

Vir said it will continue working with GSK to “ensure ongoing access to sotrovimab for patients worldwide, where authorized.” It will retain full control of Covid-19 assets previously covered by the collaboration, for which it will pay low- to mid-single digit royalties on any candidates that come to market.

Independently or in collaboration with other partners, Vir said it plans to continue developing next-generation Covid candidates.

Author: Dede Williams, Freelance Journalist

© David Marchal/iStockphoto
© David Marchal/iStockphoto

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.